Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W. Green acquired 10,000 shares of Harvard Bioscience stock in a transaction dated Friday, August 16th. The shares were bought at an average cost of $2.49 per share, for a total transaction of $24,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ HBIO opened at $2.76 on Thursday. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.52 and a quick ratio of 1.30. The stock has a market capitalization of $95.11 million, a PE ratio of 18.40 and a beta of 1.51. Harvard Bioscience, Inc. has a 1 year low of $1.51 and a 1 year high of $6.26. The business’s 50-day moving average is $2.20 and its 200 day moving average is $3.00.
Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The company had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $29.30 million. Harvard Bioscience had a positive return on equity of 5.24% and a negative net margin of 0.46%. As a group, equities research analysts anticipate that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Harvard Bioscience by 2.5% in the 4th quarter. BlackRock Inc. now owns 3,067,176 shares of the medical instruments supplier’s stock worth $9,754,000 after acquiring an additional 73,423 shares during the last quarter. Engine Capital Management LP bought a new position in Harvard Bioscience in the 2nd quarter worth $3,736,000. Dalton Greiner Hartman Maher & Co. boosted its holdings in Harvard Bioscience by 1,164.5% in the 2nd quarter. Dalton Greiner Hartman Maher & Co. now owns 1,117,421 shares of the medical instruments supplier’s stock worth $2,235,000 after buying an additional 1,029,052 shares during the period. Acadian Asset Management LLC boosted its holdings in Harvard Bioscience by 36.5% in the 2nd quarter. Acadian Asset Management LLC now owns 1,052,028 shares of the medical instruments supplier’s stock worth $2,103,000 after buying an additional 281,293 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Harvard Bioscience by 45.0% in the 2nd quarter. Renaissance Technologies LLC now owns 901,000 shares of the medical instruments supplier’s stock worth $1,802,000 after buying an additional 279,500 shares during the period. 72.86% of the stock is currently owned by institutional investors.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Recommended Story: How much money do you need to begin day trading?
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.